Literature DB >> 8903479

Expression of laminin in renal-cell carcinomas, renal-cell carcinoma cell lines and xenografts in nude mice.

J Lohi1, T Tani, I Leivo, A Linnala, L Kangas, R E Burgeson, V P Lehto, I Virtanen.   

Abstract

We studied the expression of laminin (Ln) chains (alpha1-alpha3, beta1-beta3, gamma1) in human renal-cell carcinomas (RCC), papillary renal neoplasms (PRN) and oncocytomas, in RCC cell lines and their xenografts. In RCCs the basement membranes (BM) showed immunoreactivity for chains of Ln-1 (alpha1-beta1-gamma1). Only in well-differentiated RCCs could vessel BMs be distinguished from those of carcinoma cell islets. RCCs and oncocytomas also exhibited an abundant immunoreactivity for Ln beta2 chain in both vessel and tumor cell BMs, while Ln alpha2 chain was not seen in any renal tumors. In distinction from RCCs, PRNs presented a strong BM immunoreactivity for Ln alpha3 and beta3 chains and for Ln-5, as well as lack of Ln beta2 chain. A more variable reactivity for Ln-5 was seen in oncocytomas. As PRNs and oncocytomas have been suggested to originate from collecting ducts, it is notable that in normal human kidney, we could detect immunoreactivity for Ln-5 and its chains only in BM of the tubules of the loop of Henle. In immunoprecipitation experiments, an abundant production of Ln-1, but not of Ln-5, was seen in cultured RCC cells, while in xenografts of the same cells BM-confined immunoreactivity for both Ln-1 and Ln-5 was seen. Ln beta2 chain was produced by 2 of the 4 RCC cell lines in culture but was found only in 1 of the xenografted tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8903479     DOI: 10.1002/(SICI)1097-0215(19961104)68:3<364::AID-IJC15>3.0.CO;2-8

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

Review 1.  Laminin-5 in epithelial tumour invasion.

Authors:  Masahiko Katayama; Kiyotoshi Sekiguchi
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

2.  Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer.

Authors:  Sandra Waalkes; Faranaz Atschekzei; Mario W Kramer; Jörg Hennenlotter; Gesa Vetter; Jan U Becker; Arnulf Stenzl; Axel S Merseburger; Andres J Schrader; Markus A Kuczyk; Jürgen Serth
Journal:  BMC Cancer       Date:  2010-09-22       Impact factor: 4.430

3.  Evaluation of cellular fibronectin plasma levels as a useful staging tool in different stages of transitional cell carcinoma of the bladder and renal cell carcinoma.

Authors:  A Hegele; R Hofmann; B Kosche; J Kropf
Journal:  Biomark Insights       Date:  2007-02-07

4.  Fibronectin 1 protein expression in clear cell renal cell carcinoma.

Authors:  S Steffens; A J Schrader; Gesa Vetter; H Eggers; H Blasig; J Becker; M A Kuczyk; J Serth
Journal:  Oncol Lett       Date:  2012-01-12       Impact factor: 2.967

5.  Epithelial-mesenchymal transition downregulates laminin alpha5 chain and upregulates laminin alpha4 chain in oral squamous carcinoma cells.

Authors:  Minna Takkunen; Mari Ainola; Noora Vainionpää; Reidar Grenman; Manuel Patarroyo; Antonio García de Herreros; Yrjö T Konttinen; Ismo Virtanen
Journal:  Histochem Cell Biol       Date:  2008-05-22       Impact factor: 4.304

Review 6.  Defining the role of laminin-332 in carcinoma.

Authors:  Cherise M Guess; Vito Quaranta
Journal:  Matrix Biol       Date:  2009-08-15       Impact factor: 11.583

7.  Caspase-10, matrix metalloproteinase-9 and total laminin are correlated with the tumor malignancy of clear cell renal cell carcinoma.

Authors:  Hua Qian; Xiaoguang Li; Wei Zhang; Liang Ma; Junfeng Sun; Xianling Tang; Yongsheng Chen; Lichen Teng; Wentao Wang; Dechao Li; Yongpeng Xu; Changfu Li; Yan Cao
Journal:  Oncol Lett       Date:  2018-05-30       Impact factor: 2.967

8.  Impact of Extracellular Matrix Components to Renal Cell Carcinoma Behavior.

Authors:  Sandra Majo; Sarah Courtois; Wilfried Souleyreau; Andreas Bikfalvi; Patrick Auguste
Journal:  Front Oncol       Date:  2020-04-28       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.